title: Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonists.
abstract: A series of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins have been prepared and evaluated as in vitro and in vivo angiotensin II (Ang II) antagonists. Variation of substituents on the hydantoin ring leads to potent and selective Ang II antagonists with nanomolar IC50 values at the AT1 receptor and negligible affinity for the AT2 receptor. Preferred substituents include an n-butyl at R1 and an alkyl or heteroarylmethyl substituent at R2. The selection of the R2 substituent was guided in part by the calculation of its log P since a significant correlation was observed between CLOGP and AT1 binding affinity. The biphenyl tetrazole pharmacophore, common to a number of AT1 antagonists, could be replaced by, for example, a 4-carbomethoxyphenyl substituent resulting in potent Ang II antagonists both in vitro and in vivo. A representative compound of this series is 57, which reduced the mean arterial blood pressure of renal hypertensive rats by 40% at 30 mg/kg po and by 25% at 10 mg/kg po. In addition this compound was efficacious in the salt-deplete normotensive monkey model maximally decreasing blood pressure 27% at 10 mg/kg po. In summary, these compounds belong to a novel class of Ang II antagonists that lack the biphenyl tetrazole moiety yet display appreciable and long lasting oral activity.
authors.affiliation: Department of Chemistry and Pharmacology, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48106-1047, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Edmunds
authors.forename: S
authors.initials: S
authors.lastname: Klutchko
authors.forename: J M
authors.initials: JM
authors.lastname: Hamby
authors.forename: A M
authors.initials: AM
authors.lastname: Bunker
authors.forename: C J
authors.initials: CJ
authors.lastname: Connolly
authors.forename: R T
authors.initials: RT
authors.lastname: Winters
authors.forename: J
authors.initials: J
authors.lastname: Quin
authors.forename: I
authors.initials: I
authors.lastname: Sircar
authors.forename: J C
authors.initials: JC
authors.lastname: Hodges
authors.forename: R L
authors.initials: RL
authors.lastname: Panek
mesh_terms: D000284:Administration, Oral; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000378:metabolism; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000959:Antihypertensive Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D001011:Aorta / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D000882:Haplorhini; D006827:Hydantoins / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D006973:Hypertension / Q000188:drug therapy; D066298:In Vitro Techniques; D008297:Male; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D011945:Receptors, Angiotensin / Q000378:metabolism; D013329:Structure-Activity Relationship; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D006827:Hydantoins; D011945:Receptors, Angiotensin; D000804:Angiotensin II